Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was just about ready to ask about that.
How do you know that was panic sellers and not someone shorting the stock?
So you admit you have no idea what their hiring strategy is but yet you are here bashing it. I don't get it. Patience is required here.
I think he is saying that his friends do not like this stock at this price. That doesn't mean they wouldn't like it if they were able to purchase it much lower. They don't like that retail has these shares locked up and they have not been able to drive the price lower.
Amarin has gone full board at educating physicians during this period. I have never seen an sNDA promoted so effectively prior to FDA actual approval. 400 reps + management + KOLs + managed care folks are out there now preparing the prescribers and the insurance companies for what is about to happen.
I think we will hear more about expansion plans tomorrow and next Wednesday. We need to get the expanded label and better insurance coverage before they go so strongly after it. The company has not done a presentation since priority review was announced. I know it is hard when we are sitting on a goldmine. Short interest and those that want your shares have been working hard to try and steal your shares. IMO, they are about to be in for a rude awakening.
It is interesting. Vascepa lowers the same inflammation and crosses the blood brain barrier. I wish there was a second study going on and not just the one with the VA.
Yes, it can be done before the PDUFA date.
"none of us know what the f@$k is going on here" Please speak for yourself and not others. Message board etiquette 101.
Sometimes market caps get ahead of where the market cap should be, or what the institutions think the market cap should be. I think when AMRN went to 23, it got ahead of itself. That doesn't mean it will not be back there and much higher soon.
It looks like they have a prior authorization process to get them to cover it.
This is why getting the expanded label 4 months earlier is so important. Vascepa will be the only drug for the indication. Did he use the coupon?
AMRN has been at every single conference related to cardio/lipids and diabetes since reduce-it results came out. Major presentations have occurred. Banners have been flown and more banners will be at the ADA coming up. But don't look at that. It is all about a number to some of you. 400 vs 1000. If you have 400 already, a 1000 is easy when it is time. Vascepa Commercial during Jeopardy last night was brilliant but don't give them credit for that.
He will have to update guidance at some point. We are two months into the next quarter.
Current 2019 revenue is now projected higher than current guidance. Even without expanded label, the guidance needs to be updated. Analyst have agreed. The CEO here gets it.
I really thought the Priority Review would eliminate some of the paranoia here regarding the FDA. Science will prevail and we all know how good the science is here. Every study that comes out is positive. All of the anecdotal evidence is positive. More than five years on the market and side effects posted on the FDA website are minimal.
This may sound harsh but It is easy to mix up what is good for the masses and what is good for shareholders. A buyout may benefit humanity but going it alone with benefit shareholders in the long term.
Those that recently realized what we have here want you to be impatient and they want you to sell your shares to them at a lower price. They have increased short interest to high levels which has lowered the share price. It is probably true that the market cap got a little ahead of it self, prior to approval but it will rebound. Once the shorts start covering as revenue increases, the share price will recover. I understand that many here now has large sums of money at risk. Calm down people. Go enjoy your life and be patient.
You do realize don't you that they have 400 reps + managers and lols and are at every cardio/diabetes conference.
If the GIA in the US, they will partner Europe and have plenty of COH.
You might want to pay attention to the revenue and the increases in scripts. They are taking 10% of the revenue to pay off the debt and the debt will be paid off very soon.
Updating revenue guidance for the rest of the year will be a catalyst very soon.
212 M in cash + receivables and only 80 M in debt. They do not need to do a raise.
It is a very big effort. Short interest keeps growing.
XBI and IBB are positive this morning. AMRN should follow.
June Investor Presentation
https://investor.amarincorp.com/static-files/6eca1aa8-cf50-4d4d-a181-a5202f6942cc
This is an Amarin board, get this rare earth crap off this message board.
Yes, 60 to 74 days means just that.
This could really be something. My Mom died of Pancreatic cancer. I would love to be a part of something that would help those down the road.
EphA2, is overexpressed in breast, pancreatic, prostate, lung, and colon cancers.
JL, what would the next steps be?
"combination that uses either genetic segments to prevent the function of the tumor's EPHA2 receptors or agents which destroy the receptors..."
Does such a drug exist that can prevent the function of the EPHA2 receptor?
He is in Ft. Myers, Florida
I wouldn't believe anything I read on the Yahoo message board.
Not sure why a smaller label group would make a priority review more likely. I would think a broader label of unmet need would be given the same or more priority. It seem you are helping the case for priority review.
Jefferies note from May 1 states -
sNDA label expansion review getting underway...
The company reiterated they submitted the sNDA for the CVOT label expansion (3/28) and expect FDA acceptance within 60-74 days (est end of May to first half of June) and planning for an ADCOM review panel and standard review timeclock, putting a PDUFA around January 2020. We believe most investors expect a panel given this is a major landmark CVOT that has broad implications for millions of potential patients though we could also see a scenario where there is no panel given there really isn't any issue or debate that would truly require a panel to discuss it for a whole day and on a drug that is already FDA-approved. We see no read-through either way.
He is an anti-vaxxer prone to believing conspiracy theories. His whole family has come out against him on this issue.
If there is no reason to raise money short interest is not going to hurt you like it would if you need to raise capital.
Short interest is 17% of the available float right now, that is a big deal.
Was there 23 Million shares short AMRN in September? I just looked, there was only 12 Million. It should be epic when it happens.
I see my internal medicine doc on Wednesday for my annual physical. I have not been in to her office in a year and I feel great. I have not seen her since Reduce-it results so I will be asking questions if she knows about the study results and whether she now has anyone else taking Vascepa. She wrote her first Vascepa prescription for me after my previous physician left practice.
My test results just came back and I checked online and my trigs/cholesterol look good so I will focus on her knowledge to see what she has heard over the last year and whether she is prescribing to others. If she mentions cost I can tell her from personal experience that Express Scripts changes earlier this year has now made my out of pocket $9.
Why would you not wait until the end of day when the actual 3/31 filings need to be filed? It is a ridiculous time to say that the filings have not changed.
From your post - "As of 05-15-2019 institutional holdings remain range bound at 48% during the 1st quarter ending on 03-31-2019..... so Baker Brothers or anyone else is not involved with making the share prices erode downward just to be picked up cheaper..... "
There may still be a PR out about it and what is going on at the Lipid meeting this weekend in Miami.
If anyone thinks they are going to buy back shares at the bottom might want to look at the chart today.